In relation to the decision on whether a deal will be made or not on Brexit, the outcome will have a big threat on pharmaceutical research and manufacturing in the United Kingdom, the industry has said. This will potentially be driving up manufacturing costs and minimising future investment. A range of companies have decided to freeze all of their manufacturing investments. Britain’s second biggest drug-maker, AstraZeneca decided to halt further investments at one of their sites in the summer of 2017. The general synopsis is that the company do not want to become an isolated island in the middle of the Atlantic Ocean. Investments are to be put on hold until there is more certainty and clarity.
There is also quite a lot of worry about post-Brexit. A major worry is a UK’s company to bring highly skilled scientists into the country, while researchers are concerned about being frozen out of EU-funded research collaborations. A no-deal Brexit would almost halve the UK’s funding from the EU’s horizon 2020 programme. Britain has also lost the European Medicines Agency (EMA) which completed its move to Amsterdam last month, with the loss of 900 jobs.
If you would like to discuss your specific requirements relating to Brexit readiness and how MIAS Pharma can help you, get in touch with us today at +353 (1) 846 3605 or email@example.com.